A method to achieve extended cannabis abstinence in cannabis dependent patients with schizophrenia and non-psychiatric controls

被引:10
|
作者
Rabin, Rachel A. [1 ,2 ]
Kozak, Karolina [1 ,2 ]
Zakzanis, Konstantine K. [4 ]
Remington, Gary [1 ,2 ,3 ,5 ]
Stefan, Cristiana [6 ]
Budney, Alan J. [7 ]
George, Tony P. [1 ,2 ,3 ]
机构
[1] Univ Toronto, Inst Med Sci, Toronto, ON, Canada
[2] CAMH, Schizophrenia Div, Toronto, ON, Canada
[3] Univ Toronto, Div Brain & Therapeut, Dept Psychiat, Toronto, ON, Canada
[4] Univ Toronto Scarborough, Dept Psychol, Scarborough, ON, Canada
[5] Campbell Family Mental Hlth Res Inst, Toronto, ON, Canada
[6] Ctr Addict & Mental Hlth, Clin Lab & Diagnost Serv, Toronto, ON, Canada
[7] Geisel Sch Med Dartmouth, Dept Psychiat, Lebanon, NH 03702 USA
关键词
Cannabis; Schizophrenia; Cannabis abstinence; Cannabis dependence; Carboxy-tetrahydrocannabinol; SERIOUS MENTAL-ILLNESS; USE DISORDERS; CONTINGENT REINFORCEMENT; MARIJUANA ABSTINENCE; DRUG-USERS; WITHDRAWAL; TOLERANCE; EXCRETION; URINE; TIME;
D O I
10.1016/j.schres.2017.05.006
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background: Cannabis use disorders (CUD) are common in schizophrenia (similar to 25%) compared to the general population (similar to 3%). Tetrahydrocannabinol (THC), the principal psychoactive component in cannabis is fat-soluble, resulting in an extended period for cannabinoid elimination. While detection of cannabinoids in urine is indicative of prior cannabis exposure, time of last use is difficult to verify sustained abstinence for extended periods (e.g., 28-days) in chronic cannabis users. Therefore, we evaluated the utility of a sustained cannabis abstinence paradigm in patients with schizophrenia and non-psychiatric controls. Methods: Cannabis dependent patients (n=19) and controls (n=20) underwent 28-days of monitored cannabis abstinence facilitated with contingency management. Urine samples were taken twice weekly. Abstinence was evaluated using 1) Self-report; 2) Qualitative biochemical confirmation using MEDTOX; and 3) in a subset of participants (schizophrenia, n = 13; controls, n = 13) gas chromatography-mass spectrometry (GC-MS) was performed to obtain quantitative creatinine-normalized carboxy-THC (THC-COOH) metabolite levels <20 ng/mL). Subjective assessments were used to assess behavioral correlates of cannabis abstinence and further supported time-dependent abstinence trajectories. Results: Abstinence rates of 42.1% (8/19) in patients and 55% (11/19) in controls (p=0.53) were observed. Increased cannabis withdrawal symptoms in both patients and controls supported abstinence. Discussion: Our results suggest a feasible method for identification of short-term cannabis abstinence in individuals with schizophrenia at rates comparable to controls. Monitoring sustained abstinence may have implications for potential interventions for CUDs in schizophrenia. (C) 2017 Elsevier B.V. All rights reserved.
引用
收藏
页码:47 / 54
页数:8
相关论文
共 50 条
  • [1] Effects of extended cannabis abstinence on clinical symptoms in cannabis dependent schizophrenia patients versus non-psychiatric controls
    Rabin, Rachel A.
    Kozak, Karolina
    Zakzanis, Konstantine K.
    Remington, Gary
    George, Tony P.
    SCHIZOPHRENIA RESEARCH, 2018, 194 : 55 - 61
  • [2] Effects of Extended Cannabis Abstinence on Cognitive Outcomes in Cannabis Dependent Patients with Schizophrenia vs Non-Psychiatric Controls
    Rachel A Rabin
    Mera S Barr
    Michelle S Goodman
    Yarissa Herman
    Konstantine K Zakzanis
    Stephen J Kish
    Michael Kiang
    Gary Remington
    Tony P George
    Neuropsychopharmacology, 2017, 42 : 2259 - 2271
  • [3] Effects of Extended Cannabis Abstinence on Cognitive Outcomes in Cannabis Dependent Schizophrenia Patients Versus Non-Psychiatric Controls
    Rabin, Rachel
    Barr, Mera
    Goodman, Michelle
    Zakzanis, Konstantine
    Kish, Stephen
    Kiang, Michael
    Remington, Gary
    George, Tony
    NEUROPSYCHOPHARMACOLOGY, 2016, 41 : S401 - S402
  • [4] Effects of Extended Cannabis Abstinence on Cognitive Outcomes in Cannabis Dependent Patients with Schizophrenia vs Non-Psychiatric Controls
    Rabin, Rachel A.
    Barr, Mera S.
    Goodman, Michelle S.
    Herman, Yarissa
    Zakzanis, Konstantine K.
    Kish, Stephen J.
    Kiang, Michael
    Remington, Gary
    George, Tony P.
    NEUROPSYCHOPHARMACOLOGY, 2017, 42 (11) : 2259 - 2271
  • [5] Effects of Extended Cannabis Abstinence on Clinical and Cognitive Symptoms in Cannabis Dependent Patients with Schizophrenia and Non-Psychiatric Controls
    Rabin, Rachel
    Goodman, Michelle
    Barr, Mera
    George, Tony
    NEUROPSYCHOPHARMACOLOGY, 2015, 40 : S203 - S204
  • [6] Effects of Extended Cannabis Abstinence on Neurocognitive Outcomes in Cannabis Dependent Schizophrenia Patients versus Non-Psychiatric Controls
    George, Tony
    Rabin, Rachel
    AMERICAN JOURNAL ON ADDICTIONS, 2017, 26 (03): : 242 - 242
  • [7] Changes in tobacco consumption in cannabis dependent patients with schizophrenia versus non-psychiatric controls during 28-days of cannabis abstinence
    Rabin, Rachel A.
    Dermody, Sarah S.
    George, Tony P.
    DRUG AND ALCOHOL DEPENDENCE, 2018, 185 : 181 - 188
  • [8] Examining 28-Day Abstinence on P300 in Cannabis Dependent Patients With Schizophrenia Compared to Non-Psychiatric Controls
    Barr, Mera
    Rabin, Rachel
    Zomorrodi, Reza
    Kiang, Michael
    Kozak, Karolina
    Rajji, Tarek
    Daskalakis, Zafiris
    George, Tony
    NEUROPSYCHOPHARMACOLOGY, 2016, 41 : S256 - S257
  • [9] Examining 28-Day Abstinence on P300 in Cannabis Dependent Patients with Schizophrenia Compared to Non-Psychiatric Controls
    Barr, Mera
    Kiang, Michael
    Zomorrodi, Reza
    Kozak, Karolina
    Goodman, Michelle
    Rabin, Rachel
    Rajji, Tarek
    Daskalakis, Zafiris
    George, Tony
    AMERICAN JOURNAL ON ADDICTIONS, 2017, 26 (03): : 254 - 254
  • [10] Examining Working Memory Evoked Gamma Oscillations in Cannabis Dependent Patients with Schizophrenia and Non-psychiatric Controls
    Barr, Mera S.
    Goodman, Michelle S.
    Rabin, Rachel A.
    Daskalakis, Zafiris J.
    George, Tony P.
    NEUROPSYCHOPHARMACOLOGY, 2014, 39 : S626 - S626